# Guardant Health, Inc.: financial statements, quarterly

GH · Nasdaq · CIK 1576280 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/gh.md) · [Financials](/companies/gh/financials.md) · [Filings](/companies/gh/filings.md) · [Insiders](/companies/gh/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/gh/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [143](/filings/0001576280-24-000261.md) | [155 d](/filings/0001576280-26-000013.md) | [168](/filings/0001576280-25-000136.md) | [177](/filings/0001576280-25-000246.md) | [191](/filings/0001576280-25-000277.md) | [202 d](/filings/0001576280-26-000013.md) | [203](/filings/0001576280-26-000026.md) | [232](/filings/0001576280-26-000037.md) | [265](/filings/0001576280-25-000277.md) | [281 d](/filings/0001576280-26-000013.md) | [302](/filings/0001576280-26-000026.md) | [335](/filings/0001576280-26-000037.md) |
| Cost of revenue | $m | not reported | not reported | [65.3](/filings/0001576280-25-000136.md) | [72.4](/filings/0001576280-25-000246.md) | [74.5](/filings/0001576280-25-000277.md) | [77.6 d](/filings/0001576280-26-000013.md) | [74.7](/filings/0001576280-26-000026.md) | [81.2](/filings/0001576280-26-000037.md) | [93.6](/filings/0001576280-25-000277.md) | [99.5 d](/filings/0001576280-26-000013.md) | [105](/filings/0001576280-26-000026.md) | [116](/filings/0001576280-26-000037.md) |
| Research and development | $m | [93.9](/filings/0001576280-24-000261.md) | [89.9 d](/filings/0001576280-26-000013.md) | [83.8](/filings/0001576280-25-000136.md) | [83.1](/filings/0001576280-25-000246.md) | [87.3](/filings/0001576280-25-000277.md) | [93.5 d](/filings/0001576280-26-000013.md) | [88.5](/filings/0001576280-26-000026.md) | [87.4](/filings/0001576280-26-000037.md) | [90.0](/filings/0001576280-25-000277.md) | [98.3 d](/filings/0001576280-26-000013.md) | [91.0](/filings/0001576280-26-000026.md) | [96.5](/filings/0001576280-26-000037.md) |
| Operating income | $m | [(114)](/filings/0001576280-24-000261.md) | [(198) d](/filings/0001576280-26-000013.md) | [(99.7)](/filings/0001576280-25-000136.md) | [(101)](/filings/0001576280-25-000246.md) | [(117)](/filings/0001576280-25-000277.md) | [(126) d](/filings/0001576280-26-000013.md) | [(111)](/filings/0001576280-26-000026.md) | [(106)](/filings/0001576280-26-000037.md) | [(99.0)](/filings/0001576280-25-000277.md) | [(121) d](/filings/0001576280-26-000013.md) | [(121)](/filings/0001576280-26-000026.md) | [(129)](/filings/0001576280-26-000037.md) |
| Interest expense | $m | [0.6](/filings/0001576280-23-000187.md) | [0.6 d](/filings/0001576280-24-000043.md) | [0.6](/filings/0001576280-24-000109.md) | [0.6](/filings/0001576280-25-000246.md) | [0.6](/filings/0001576280-25-000277.md) | [0.6 d](/filings/0001576280-26-000013.md) | [0.8](/filings/0001576280-26-000026.md) | [1.0](/filings/0001576280-26-000037.md) | [0.9](/filings/0001576280-25-000277.md) | [1.2 d](/filings/0001576280-26-000013.md) | [1.3](/filings/0001576280-26-000026.md) | [1.3](/filings/0001576280-26-000037.md) |
| Income tax | $m | [0.5](/filings/0001576280-24-000261.md) | [(0.5) d](/filings/0001576280-26-000013.md) | [0.4](/filings/0001576280-25-000136.md) | [0.1](/filings/0001576280-25-000246.md) | [0.0](/filings/0001576280-25-000277.md) | [0.7 d](/filings/0001576280-26-000013.md) | [0.3](/filings/0001576280-26-000026.md) | [0.0](/filings/0001576280-26-000037.md) | [0.1](/filings/0001576280-25-000277.md) | [(1.7) d](/filings/0001576280-26-000013.md) | [0.4](/filings/0001576280-26-000026.md) | [0.2](/filings/0001576280-26-000037.md) |
| Net income | $m | [(86.1)](/filings/0001576280-24-000261.md) | [(187) d](/filings/0001576280-26-000013.md) | [(115)](/filings/0001576280-25-000136.md) | [(103)](/filings/0001576280-25-000246.md) | [(108)](/filings/0001576280-25-000277.md) | [(111) d](/filings/0001576280-26-000013.md) | [(95.2)](/filings/0001576280-26-000026.md) | [(99.9)](/filings/0001576280-26-000037.md) | [(92.7)](/filings/0001576280-25-000277.md) | [(128) d](/filings/0001576280-26-000013.md) | [(112)](/filings/0001576280-26-000026.md) | [(120)](/filings/0001576280-26-000037.md) |
| Diluted EPS | $ per share | [(0.73)](/filings/0001576280-24-000261.md) | not reported | [(0.94)](/filings/0001576280-25-000136.md) | [(0.84)](/filings/0001576280-25-000246.md) | [(0.88)](/filings/0001576280-25-000277.md) | not reported | [(0.77)](/filings/0001576280-26-000026.md) | [(0.80)](/filings/0001576280-26-000037.md) | [(0.74)](/filings/0001576280-25-000277.md) | not reported | [(0.85)](/filings/0001576280-26-000026.md) | [(0.90)](/filings/0001576280-26-000037.md) |
| Basic EPS | $ per share | [(0.73)](/filings/0001576280-24-000261.md) | not reported | [(0.94)](/filings/0001576280-25-000136.md) | [(0.84)](/filings/0001576280-25-000246.md) | [(0.88)](/filings/0001576280-25-000277.md) | not reported | [(0.77)](/filings/0001576280-26-000026.md) | [(0.80)](/filings/0001576280-26-000037.md) | [(0.74)](/filings/0001576280-25-000277.md) | not reported | [(0.85)](/filings/0001576280-26-000026.md) | [(0.90)](/filings/0001576280-26-000037.md) |

- Revenue: us-gaap:Revenues, us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [457](/filings/0001576280-24-000261.md) | [1,134](/filings/0001576280-26-000013.md) | [1,029](/filings/0001576280-25-000136.md) | [934](/filings/0001576280-25-000246.md) | [585](/filings/0001576280-25-000277.md) | [526](/filings/0001576280-26-000013.md) | [699](/filings/0001576280-26-000026.md) | [629](/filings/0001576280-26-000037.md) | [580](/filings/0001576280-25-000277.md) | [378](/filings/0001576280-26-000037.md) | [989](/filings/0001576280-26-000026.md) | [1,053](/filings/0001576280-26-000037.md) |
| Current assets | $m | [1,347](/filings/0001576280-23-000187.md) | [1,347](/filings/0001576280-25-000044.md) | [1,309](/filings/0001576280-24-000109.md) | [1,290](/filings/0001576280-24-000190.md) | [1,227](/filings/0001576280-24-000261.md) | [1,055](/filings/0001576280-26-000013.md) | [927](/filings/0001576280-25-000136.md) | [883](/filings/0001576280-25-000246.md) | [829](/filings/0001576280-25-000277.md) | [1,466](/filings/0001576280-26-000037.md) | [1,368](/filings/0001576280-26-000026.md) | [1,365](/filings/0001576280-26-000037.md) |
| Total assets | $m | [1,797](/filings/0001576280-23-000187.md) | [1,786](/filings/0001576280-25-000044.md) | [1,705](/filings/0001576280-24-000109.md) | [1,609](/filings/0001576280-24-000190.md) | [1,539](/filings/0001576280-24-000261.md) | [1,486](/filings/0001576280-26-000013.md) | [1,344](/filings/0001576280-25-000136.md) | [1,332](/filings/0001576280-25-000246.md) | [1,277](/filings/0001576280-25-000277.md) | [2,014](/filings/0001576280-26-000037.md) | [1,915](/filings/0001576280-26-000026.md) | [1,912](/filings/0001576280-26-000037.md) |
| Current liabilities | $m | [227](/filings/0001576280-23-000187.md) | [206](/filings/0001576280-25-000044.md) | [220](/filings/0001576280-24-000109.md) | [202](/filings/0001576280-24-000190.md) | [197](/filings/0001576280-24-000261.md) | [226](/filings/0001576280-26-000013.md) | [226](/filings/0001576280-25-000136.md) | [238](/filings/0001576280-25-000246.md) | [237](/filings/0001576280-25-000277.md) | [303](/filings/0001576280-26-000037.md) | [292](/filings/0001576280-26-000026.md) | [339](/filings/0001576280-26-000037.md) |
| Total liabilities | $m | [1,569](/filings/0001576280-23-000187.md) | [1,628](/filings/0001576280-25-000044.md) | [1,636](/filings/0001576280-24-000109.md) | [1,611](/filings/0001576280-24-000190.md) | [1,599](/filings/0001576280-24-000261.md) | [1,625](/filings/0001576280-26-000013.md) | [1,595](/filings/0001576280-25-000136.md) | [1,637](/filings/0001576280-25-000246.md) | [1,631](/filings/0001576280-25-000277.md) | [2,113](/filings/0001576280-26-000037.md) | [2,096](/filings/0001576280-26-000026.md) | [2,135](/filings/0001576280-26-000037.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | [1,143](/filings/0001576280-26-000013.md) | [1,116](/filings/0001576280-25-000136.md) | [1,116](/filings/0001576280-25-000246.md) | [1,115](/filings/0001576280-25-000277.md) | [1,504](/filings/0001576280-26-000037.md) | [1,503](/filings/0001576280-26-000026.md) | [1,503](/filings/0001576280-26-000037.md) |
| Shareholders' equity | $m | [228](/filings/0001576280-24-000261.md) | [159](/filings/0001576280-26-000013.md) | [68.3](/filings/0001576280-25-000246.md) | [(1.6)](/filings/0001576280-25-000277.md) | [(60.1)](/filings/0001576280-25-000277.md) | [(140)](/filings/0001576280-26-000037.md) | [(251)](/filings/0001576280-26-000037.md) | [(305)](/filings/0001576280-26-000037.md) | [(354)](/filings/0001576280-25-000277.md) | [(99.3)](/filings/0001576280-26-000037.md) | [(181)](/filings/0001576280-26-000037.md) | [(223)](/filings/0001576280-26-000037.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebt
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(77.8) d](/filings/0001576280-24-000261.md) | [(78.7) d](/filings/0001576280-26-000013.md) | [(30.3)](/filings/0001576280-25-000136.md) | [(94.0) d](/filings/0001576280-25-000246.md) | [(51.1) d](/filings/0001576280-25-000277.md) | [(64.5) d](/filings/0001576280-26-000013.md) | [(62.7)](/filings/0001576280-26-000026.md) | [(60.3) d](/filings/0001576280-26-000037.md) | [(35.4) d](/filings/0001576280-25-000277.md) | [(26.4) d](/filings/0001576280-26-000013.md) | [(65.6)](/filings/0001576280-26-000026.md) | [(57.8) d](/filings/0001576280-26-000037.md) |
| Capital expenditure | $m | [2.4 d](/filings/0001576280-24-000261.md) | [4.1 d](/filings/0001576280-26-000013.md) | [6.9](/filings/0001576280-25-000136.md) | [5.1 d](/filings/0001576280-25-000246.md) | [4.2 d](/filings/0001576280-25-000277.md) | [18.9 d](/filings/0001576280-26-000013.md) | [4.5](/filings/0001576280-26-000026.md) | [5.6 d](/filings/0001576280-26-000037.md) | [10.4 d](/filings/0001576280-25-000277.md) | [27.8 d](/filings/0001576280-26-000013.md) | [5.6](/filings/0001576280-26-000026.md) | [11.8 d](/filings/0001576280-26-000037.md) |
| Share repurchases | $m | not reported | not reported | [0.0](/filings/0001576280-25-000136.md) | [0.0 d](/filings/0001576280-25-000246.md) | [0.0 d](/filings/0001576280-25-000277.md) | [0.0 d](/filings/0001576280-26-000013.md) | [45.0](/filings/0001576280-26-000026.md) | [0.0 d](/filings/0001576280-26-000037.md) | [0.0 d](/filings/0001576280-25-000277.md) | [0.0 d](/filings/0001576280-26-000013.md) | [0.0](/filings/0001576280-26-000026.md) | [0.0 d](/filings/0001576280-26-000037.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [102](/filings/0001576280-23-000187.md) | [103](/filings/0001576280-24-000109.md) | [109](/filings/0001576280-24-000190.md) | [118](/filings/0001576280-24-000261.md) | [122](/filings/0001576280-25-000136.md) | [122](/filings/0001576280-25-000246.md) | [123](/filings/0001576280-25-000277.md) | [124](/filings/0001576280-26-000026.md) | [124](/filings/0001576280-26-000037.md) | [125](/filings/0001576280-25-000277.md) | [131](/filings/0001576280-26-000026.md) | [133](/filings/0001576280-26-000037.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 134,196,170 at 2026-07-24, from the cover of the [10-Q filed 2026-07-30](/filings/0001576280-26-000037.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:43 ET. No prices; not investment advice.